| Similar Articles |
|---|
 |
Managed Care
March 2005
Martin Sipkoff |
Direct-to-Consumer Ads Garner Mixed Outcomes DTC advertising's reputation as a bully may be largely overstated. There's little evidence that sales of specific drugs increase, and there may be some benefit.   |
BusinessWeek
August 15, 2005
Barrett & Weintraub |
Drugmakers Are Changing Channels All those "Ask your doctor if it's right for you" ads on TV haven't delivered. As drugmakers labor to develop more educational and balanced pitches, they're also trying to better target their messages. |
BusinessWeek
August 13, 2007
Arlene Weintraub |
Putting Drug Ads Back In The Bottle Efforts to curb direct-to-consumer drug advertising are growing, but so far have met little success. |
BusinessWeek
February 9, 2004
John Carey |
Drug Ads Need Stronger Medicine New FDA guidelines may not go far enough in making sure pharmaceutical ads are used appropriately. |
Pharmaceutical Executive
May 1, 2007
Diane West |
Spend Trends 2007: Hang 10 Direct-to-Consumer Advertising Hits Its First Decade: Dr. Dot-Com... Digital Detailing... etc. |
Pharmaceutical Executive
October 1, 2010 |
Optimizing TV Advertising Placements & Results Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
September 18, 2008
Brian Orelli |
Medical Device Makers Throwing Money Down the Tube Congress is investigating medical device makers' direct-to-consumer ads. |
The Motley Fool
September 2, 2008
Brian Orelli |
Lipitor Is Back on the Tube Direct-to-consumer ads have to walk a line. |
Pharmaceutical Executive
April 1, 2006
Diane West |
Media Spend Trends: Change the Channel Drug marketers still spend lots of money. But they aim at PhRMA loopholes. |
The Motley Fool
February 26, 2010
Brian Orelli |
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. |
The Motley Fool
December 11, 2008
Brian Orelli |
Drugmakers Could Lose Their Greatest Weapon Congress is thinking about putting limits on direct-to-consumer advertisements. The pharmaceutical industry trade group makes a preemptive strike. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
BusinessWeek
March 7, 2005
Amy Barrett |
Will Drugmakers Back Off The Hard Sell? Drug ads need to return to more balanced communication of risks and benefits and not depend so much on catchy phrases and images. The question is whether the industry is ready to take that lesson to heart. |
Salon.com
May 8, 2001
Daryl Lindsey |
The "Joe Camel" ads of AIDS? The FDA says ads for drugs to suppress HIV are making false promises, and could be contributing to an epidemic of unsafe sex... |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
BusinessWeek
November 19, 2009
Catherine Arnst |
Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions. |
Managed Care
February 2007
MargaretAnn Cross |
How Much Trouble Does Health Care Marketing Cause? Whether for drugs, imaging, surgery, or emergency services, direct-to-consumer advertising sparks lively debate. |
Pharmaceutical Executive
June 1, 2007
Stan Bernard |
Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive
May 1, 2005
Diane West |
Media Spend Trends: Changing Lanes You've got their attention---now what? Pharma marketing analysts predict a spending shift from branded direct-to-consumer efforts to more disease awareness and corporate reputation promotions. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
Pharmaceutical Executive
June 1, 2006
Philip A. George |
Alternative Media: Online Med Sites Gain Patient Trust Pharma could benefit from a little less TV. |
BusinessWeek
February 28, 2005
David Kiley |
The Little Blue Pill -- And Pals -- Have The Blues Despite gargantuan ad budgets, sales are trailing expectations for all three erectile dysfunction contenders. |
Pharmaceutical Executive
November 1, 2008
Brittany Agro |
Docs Rock the Vote Medical journal advertising takes center stage at the sixth-annual Doctor's Choice Awards. |
Pharmaceutical Executive
September 1, 2006
Jeannette Park |
Directo to Consumer: No-Name Opportunity Marketers are using unbranded ads to get across the right messages. |
The Motley Fool
October 26, 2010
Brian Orelli |
Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth. |
The Motley Fool
June 11, 2010
Brian Orelli |
Pfizer and Bristol Coagulate Against Clots Let's see how apixaban does against warfarin before we break out the "blockbuster" stamp. |
The Motley Fool
June 2, 2010
Brian Orelli |
Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it." |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
The Motley Fool
March 11, 2010
Brian Orelli |
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. |
The Motley Fool
June 2, 2010
Brian Orelli |
Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market. |
Pharmaceutical Executive
July 30, 2007 |
Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations. |
The Motley Fool
May 18, 2010
Brian Orelli |
Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
Pharmaceutical Executive
February 1, 2007 |
Marketing to Professionals: Resource Allocation A Stanford professor schools pharma on professional marketing. |
Chemistry World
April 14, 2008
Ananyo Bhattacharya |
Psychiatric Drug Ads 'Frequently Misleading' Advertisements for psychiatric drugs - including many top-selling antidepressants - often make claims that are either misleading or impossible to verify, according to a new US study. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Pharmaceutical Executive
September 1, 2005
Mittman & Secor |
Direct to Consumer: Perpetuating Prescribing Myths Misleading language in direct to consumer drug ads leads to patient confusion and the frustration of nurse practitioners and physician assistants. |
Pharmaceutical Executive
September 1, 2010 |
To Brand or Not to Brand? The effectiveness of direct-to-consumer prescription advertising hinges on a consumer's thirst for information. A new study intimates the less info consumers are given up front, the more they seem willing to learn. |
Salon.com
March 12, 2002
Janelle Brown |
Saying no to propaganda Critics say the government's new anti-drug campaign is reactionary and moralistic. Worse, it may not even work... |
The Motley Fool
January 8, 2008
Brian Orelli |
A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
March 15, 2010
Brian Orelli |
Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison. |
